Selective ETA Receptor Blockade for IgA Nephropathy Renal Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for IgA nephropathy (IgAN) provide only supportive care and are associated with adverse reactions, leading to a high progression rate to end-stage renal disease (ESRD) with significant quality of life degradation, while the role of endothelin A (ETA) receptor in mesangial cell activation has not been previously explored.
Innovation Solution
Administering atrasentan, a selective ETA receptor antagonist, to inhibit mesangial cell activation and associated pathways in IgA nephropathy, thereby reducing inflammation, fibrosis, and progression of the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches (ACE inhibitors, ARBs, immunosuppressive drugs) are used to treat IgA nephropathy, then supportive care is provided, but adverse reactions occur and disease progression to ESRD continues at high rates
Solution Approach 1:
The patent changes the therapeutic parameter from conventional ACE inhibitors/ARBs/immunosuppressants to selective ETA receptor antagonists (atrasentan), which specifically block endothelin A receptor signaling. This parameter change achieves better disease progression control while reducing adverse reactions by targeting the specific endothelin pathway involved in IgA nephropathy pathogenesis
Solution Approach 2:
The patent introduces atrasentan as an intermediary substance that selectively blocks ETA receptor activation. This intermediary prevents the harmful effects of endothelin-1 binding to ETA receptors on mesangial cells, thereby controlling disease progression without the broad-spectrum adverse effects of conventional immunosuppressive therapies
2Reliability
If ACE inhibitors or ARBs are administered at maximum tolerable doses to provide supportive care, then renal function is supported, but adverse reactions outweigh benefits
Solution Approach 1:
The patent transitions from non-selective renin-angiotensin system inhibition to selective endothelin A receptor antagonism. This parameter change maintains renal function support through specific ETA blockade while avoiding the dose-limiting adverse reactions of maximum-dose ACE inhibitors or ARBs
Solution Approach 2:
The patent employs a targeted, mechanism-specific therapeutic approach that achieves therapeutic effect at lower doses with fewer side effects, replacing the need for high-dose conventional therapy that produces intolerable adverse reactions
3Reliability
If immunosuppressive drugs are administered to treat IgA nephropathy, then disease activity is suppressed, but benefits are largely outweighed by adverse reactions
Solution Approach 1:
The patent changes the therapeutic mechanism from broad immunosuppression to specific endothelin A receptor blockade. This selective targeting suppresses disease activity by preventing ETA-mediated mesangial cell activation while avoiding the severe immunosuppressive adverse reactions
Solution Approach 2:
The patent uses atrasentan as a selective intermediary that blocks the specific endothelin-1/ETA receptor interaction driving IgA nephropathy progression, replacing broad immunosuppressive agents with a mechanism-specific blocker that has a favorable safety profile
4Reliability
If selective ETA receptor antagonists are used to block ETA function, then beneficial renal effects (vasodilation, reduced inflammation) are achieved, but sodium and water retention increases
Solution Approach 1:
The patent employs selective ETA receptor antagonism that specifically targets endothelin A receptors on renal mesangial cells and vascular endothelium. This local quality approach provides beneficial renal effects (vasodilation, anti-inflammation) at the target site while minimizing systemic sodium and water retention through selective rather than non-selective blockade
Data Source
AI summary
Provided herein are methods of improving kidney function in a subject in need thereof.